PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
187.54%
Cash & equivalents yoy growth at least 1.5x RVPH's 95.93%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
187.23%
Cash + STI yoy ≥ 1.5x RVPH's 95.93%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
168.93%
≥ 1.5x RVPH's 72.84%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-20.60%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.19%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
164.96%
≥ 1.5x RVPH's 64.40%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-45.35%
Less than half of RVPH's 5.25%. David Dodd sees a more disciplined AP approach or lower volume.
-33.08%
50-75% of RVPH's -49.51%. Bruce Berkowitz notes the firm is less reliant on near-term borrowing than competitor.
No Data
No Data available this quarter, please select a different quarter.
43.64%
Higher Deferred Revenue (Current) Growth compared to RVPH's zero value, indicating better performance.
-68.51%
Less than half of RVPH's 8.21%. David Dodd sees fewer expansions in other current obligations.
-61.96%
Less than half of RVPH's 4.94%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-61.96%
Less than half of RVPH's 4.83%. David Dodd sees far fewer liability expansions relative to competitor.
19.13%
Less than half of RVPH's 45.49%. David Dodd sees fewer share issuances vs. competitor.
-3.37%
Similar yoy to RVPH's -3.55%. Walter Schloss sees parallel earnings retention vs. competitor.
-26.34%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
955.36%
≥ 1.5x RVPH's 89.71%. David Dodd sees stronger capital base growth than competitor.
164.96%
≥ 1.5x RVPH's 64.40%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-33.08%
50-75% of RVPH's -49.51%. Bruce Berkowitz sees relatively smaller yoy debt additions.
-197.28%
Above 1.5x RVPH's -102.37%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.